San Diego, USand Zhengzhou, China –August 14, 2016.Granlen, Inc., San Diego and ZhengzhouGranlen PharmaTech Ltd. announced today that Dr. P. Dan Cook was appointed astheir global Chief Technology Officer and Vice President.

Dr. Cook hasbeen wellrecognized as one of the most prestigiousscientific fellow worldwidein nucleosides, oligo-nucleotides, carbohydrates, antisense, antiviral,anticancer drug discovery and development.He joins Granlen with his decades ofprecious experience.

“We areextremely pleased to have Dr. Dan Cook as one of our executive leaders atGranlen in US and its subsidiary in China.” Said Harry An, Ph. D., Founder andPresident, Granlen. “Dan’s participation adds great value to our corporatesuccess. He will definitely lead and promote Granlen’s further growth towardour leading position in nucleosides and related fields to provide betterservices to our global clients.” Dr. An added.

About Granlen– A Reliable LeadingNucleoside Pioneer!

Granlen is a global CRO to provide reliablechemistry, drug discovery and development related services for pharmaceutical, biotech,and related industries with a broad spectrum of chemistry, a wide range of drugdiscovery services, and an integrated drug development process to IND.Thehighly experienced teamswith specialty on nucleosides and related areas arecommitted to exceeding clients’ expectations and becoming your partner ofchoice. Granlen is cable of providing high quality, reliable and cost-effectivechemistry-driven drug discovery and development services.

Forward-Looking Statement

This press release may contain forward-looking statements that are subject to uncertainties. Theuncertainties could cause actual results to differ materially from thosereferred to in the forward-looking statements. All forward-looking statementsare based on information currently available to Granlen, and Granlen assumes noobligation to update any such forward-looking statements.

For further information about Granlen, please visitour website at www.granlen.comor contact:

philip.fang, philip.fang@granlen.com; +86-371-85513397

Granlen, Inc.and Zhengzhou Granlen PharmaTech Ltd.